(Q33961799)

30 July 2017

title

Accelerated lymphocyte recovery after alemtuzumab does not predict multiple sclerosis activity (English)

1 reference

30 July 2017

0 references

5

Alastair Compston

1 reference

30 July 2017

Joanne Jones

7

1 reference

ORCID Public Data File 2021

author name string

Onajite Kousin-Ezewu

1

1 reference

30 July 2017

Laura Azzopardi

2

1 reference

30 July 2017

Richard A Parker

3

1 reference

30 July 2017

Orla Tuohy

4

1 reference

30 July 2017

Alasdair Coles

6

1 reference

30 July 2017

language of work or name

English

0 references

publication date

16 May 2014

1 reference

30 July 2017

1 reference

30 July 2017

volume

82

1 reference

30 July 2017

issue

24

1 reference

30 July 2017

page(s)

2158-2164

1 reference

Human autoimmunity after lymphocyte depletion is caused by homeostatic T-cell proliferation

30 July 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4113466

Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4113466

Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4113466

Alemtuzumab more effective than interferon β-1a at 5-year follow-up of CAMMS223 clinical trial

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4113466

Alemtuzumab vs. interferon beta-1a in early multiple sclerosis

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4113466

Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4113466

Treatment of multiple sclerosis with the monoclonal anti-CD4 antibody cM-T412: results of a randomized, double-blind, placebo-controlled, MR-monitored phase II trial

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4113466

Long term lymphocyte reconstitution after alemtuzumab treatment of multiple sclerosis

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4113466

Lymphocyte homeostasis following therapeutic lymphocyte depletion in multiple sclerosis.

29 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4113466

The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy

29 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4113466

Clinical relevance of differential lymphocyte recovery after alemtuzumab therapy for multiple sclerosis

29 October 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24838790

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1212/WNL.0000000000000520

1 reference

30 July 2017

1 reference

30 July 2017

1 reference